ETON Eton Pharmaceuticals, Inc.

8-K Current Report

Filed: February 25, 2026

Health Care

Pharmaceutical Preparations

Eton Pharmaceuticals, Inc. (ETON) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• FDA approved DESMODA™ (desmopressin acetate) Oral Solution NDA for central diabetes insipidus (AVP-D) on Feb 25, 2026
• Approval covers patients of all ages, broadening addressable market vs. age-restricted indications

+2 more insights

Other Eton Pharmaceuticals, Inc. 8-K Filings

8-K Mar 19, 2026

8-K Mar 2, 2026

Get deeper insights on Eton Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.